These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29032513)

  • 1. Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved.
    Okada Y; Sato K; Kobayashi S; Nagao S; Takano K; Teramoto M; Tachi N; Kawamura T; Horiuchi T; Kato S; Saga R; Maekawa T; Yamamura T; Watanabe J; Kobayashi A; Kimura F
    Int J Hematol; 2018 Apr; 107(4):495-497. PubMed ID: 29032513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical Efficacy of Dasatinib, Nilotinib and Imatinib in Newly Diagnosed Patients with Chronic-Phase Chronic Myeloid Leukemia: A Three-year Retrospective Analysis].
    Wang YY; Zhao HG; Cui ZG; Li GL; Shi X; Xu H; Zhou Y; Zhao T
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):356-63. PubMed ID: 25948185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
    Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K
    Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
    Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
    Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
    Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.
    Tang L; Zhang H; Peng YZ; Li CG; Jiang HW; Xu M; Mei H; Hu Y
    BMC Cancer; 2019 Aug; 19(1):849. PubMed ID: 31462241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
    Cortes J; Kim DW; Raffoux E; Martinelli G; Ritchie E; Roy L; Coutre S; Corm S; Hamerschlak N; Tang JL; Hochhaus A; Khoury HJ; Brümmendorf TH; Michallet M; Rege-Cambrin G; Gambacorti-Passerini C; Radich JP; Ernst T; Zhu C; Van Tornout JM; Talpaz M
    Leukemia; 2008 Dec; 22(12):2176-83. PubMed ID: 18754032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
    Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
    Smith BD; Liu J; Latremouille-Viau D; Guerin A; Fernandez D; Chen L
    Curr Med Res Opin; 2016 May; 32(5):817-27. PubMed ID: 26743563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
    Verma D; Kantarjian HM; Jones D; Luthra R; Borthakur G; Verstovsek S; Rios MB; Cortes J
    Blood; 2009 Sep; 114(11):2232-5. PubMed ID: 19531657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of Tyrosine Kinase Inhibitors on the Th1 and Treg Cells of CML Patients].
    Dai JY; Yang X; Wei Q; Li H; Huang XB; Wang XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):25-32. PubMed ID: 30738443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
    Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
    Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
    Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
    Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.
    Kota V; Brümmendorf TH; Gambacorti-Passerini C; Lipton JH; Kim DW; An F; Leip E; Crescenzo RJ; Ferdinand R; Cortes JE
    Leuk Res; 2021 Dec; 111():106690. PubMed ID: 34673442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.